Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.40 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.37 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.37 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.32 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208998 | 0.84 | TTR (0.41) | GRM5ARTTRALBALDH1A1 | |
| SCHEMBL7929409 | 0.84 | GRM5 (0.46) | GRM5ARKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL13696502 | 0.78 | AR (0.42) | GRM5ARKCNJ6KCNJ5KCNJ3 | |
| SCHEMBL9224719 | 0.78 | EGLN2 (0.40) | GRM5TTRALBALDH1A1CYP2A6 | |
| SCHEMBL8463144 | 0.78 | GRM5 (0.43) | GRM5KCNJ6KCNJ5KCNJ3TTR | |
| SCHEMBL29891425 | 0.78 | GRM5 (0.43) | GRM5KCNJ6KCNJ5KCNJ3TTR | |
| SCHEMBL16122643 | 0.77 | GRM5 (0.42) | GRM5KCNJ6KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL16122304 | 0.77 | TSHR (0.37) | GRM5ARTTRALBALDH1A1 | |
| SCHEMBL15321757 | 0.77 | TTR (0.45) | ARKCNJ6KCNJ5KCNJ3TTR | |
| SCHEMBL15425313 | 0.75 | TTR (0.48) | GRM5TTRALBALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | UCB Biopharma SRL (BE) | 2024-02-08 | — | — | US | disclosed |
| EP-4267555-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-116507332-A | Octahydroisoquinolinyl derivatives | UCB生物制药有限责任公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022117678-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2022-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | OPRD1, OPRK1, OPRL1 | GRM5 313/4885AR 782/4885KCNJ6 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.